(Press-News.org) Researchers from Mass General Brigham have found that olezarsen—a drug designed to lower triglyceride levels—can also decrease the risk of acute pancreatitis, a potential complication in patients with severely elevated triglyceride levels. The results, from two randomized, placebo-controlled trials (CORE-TIMI 72a and CORE2-TIMI 72b), were presented at the American Heart Association Scientific Sessions and simultaneously published in The New England Journal of Medicine.
Severe hypertriglyceridemia is a condition in which the level of triglycerides (a type of fat that circulates in the blood) is very high. Approximately 1 in 100 people in the U.S. have severe hypertriglyceridemia. The condition puts people at risk for acute pancreatitis, inflammation of the pancreas that can be life-threatening.
The trials, which were designed collaboratively between the TIMI Study Group at Mass General Brigham and Ionis Pharmaceuticals, the trials’ sponsor, tested the safety and efficacy of olezarsen for reducing triglycerides and the risk of acute pancreatitis. The trials enrolled 1,063 participants across 33 countries who had fasting triglyceride levels ≥500 mg/dL and were taking lipid-lowering therapy.
“These findings support olezarsen’s potential to become a cornerstone therapy for severe hypertriglyceridemia, particularly for preventing a serious and potentially life-threating condition,” said lead author Nicholas Marston, MD, MPH, a cardiologist with the Mass General Brigham Heart and Vascular Institute. “Prevention is key in medicine, and our findings underscore the importance of clinical trials in evaluating the efficacy and safety of new treatments to improve health outcomes.”
Patients received monthly injections of olezarsen (50 mg or 80 mg) or placebo for 12 months. In 590 patients with measurements available at baseline and follow-up, more than 85% of patients taking either 50 mg or 80 mg of olezarsen saw their triglyceride levels drop below 500 mg/dL, compared with 35% in the placebo group.
There were 29 acute pancreatitis events reported across the two studies. The incidence of acute pancreatitis was 1.1 per 100 patient years in the pooled olezarsen groups, compared with 6.2 per 100 patient years in the placebo group – translating to an 85% relative risk reduction.
The long-term effectiveness and safety of olezarsen for patients with severe hypertriglyceridemia is being evaluated in an ongoing open-label extension study.
Authorship: In addition to Marston, Mass General Brigham authors include Brian A. Bergmark, Yu Mi Kang, Filipe A. Moura, Andre Zimerman, Sabina A. Murphy, Erica L. Goodrich, Shuanglu Zhang, Robert P. Giugliano, and Marc S. Sabatine. Additional authors include Veronica J. Alexander, Thomas A. Prohaska, Elaine Waldman, Julia Weinland, Shuting Xia, Dan Li, Anne C. Goldberg, Assen Goudev, Lina Badimon, Robert Gabor Kiss, Michal Vrablik, Daniel Gaudet, Philippe Moulin, Erik S.G. Stroes, Maciej Banach, Hofit Cohen, Dirk Blom, Min-Ji Charng, Børge G. Nordestgaard, Stephen J. Nicholls, and Sotirios Tsimikas.
Disclosures: The TIMI Study Group has received grant support from Ionis Pharmaceuticals for these trials. Dr. Marston has served as a consultant for Ionis Pharmaceuticals.
Funding: Both CORE-TIMI 72a and CORE2-TIMI 72b were funded by Ionis Pharmaceuticals
Paper cited: Marston NA et al. “Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk” NEJM DOI: 10.1056/NEJMoa2512761
###
About Mass General Brigham
Mass General Brigham is an integrated academic health care system, uniting great minds to solve the hardest problems in medicine for our communities and the world. Mass General Brigham connects a full continuum of care across a system of academic medical centers, community and specialty hospitals, a health insurance plan, physician networks, community health centers, home care, and long-term care services. Mass General Brigham is a nonprofit organization committed to patient care, research, teaching, and service to the community. In addition, Mass General Brigham is one of the nation’s leading biomedical research organizations with several Harvard Medical School teaching hospitals. For more information, please visit massgeneralbrigham.org.
END
Steatotic liver disease (SLD), mainly encompassing metabolic dysfunction-associated steatotic liver disease (MASLD), alcohol-related liver disease (ALD), and metabolic dysfunction and ALD (MetALD), has emerged as the dominant cause of chronic liver disease worldwide, displacing viral hepatitis as the primary aetiology. Globally, the prevalence of MASLD is estimated even over 30%, affecting over one-third of adults. Parallelly, alcohol remains a major risk factor, with heavy drinking contributing to 90–95% of SLD cases and up to 10% advancing to cancer.
Genetic ...
About The Study: The findings of this study support the routine use of sodium-glucose cotransporter 2 (SGLT2) inhibitors to improve kidney outcomes across the full spectrum of kidney function and albuminuria among patients with type 2 diabetes, chronic kidney disease, or heart failure.
Corresponding Authors: To contact the corresponding authors, email Brendon L. Neuen, PhD (bneuen@georgeinstitute.org.au) and Hiddo J. L. Heerspink, PhD (h.j.lambers.heerspink@umcg.nl).
To access the embargoed study: Visit our For The ...
In late-breaking presentations at the American Society of Nephrology Kidney Week meeting and simultaneously published in two companion papers in JAMA, the findings are based on data from over 70,000 participants across 10 major randomised controlled trials. The meta-analyses were conducted by the SGLT2 Inhibitor Meta-analysis Cardio-Renal Trialists’ Consortium (SMART-C), led by The George Institute for Global Health.
SGLT2 inhibitors, originally developed to treat type 2 diabetes, have since demonstrated substantial protection against heart failure and chronic ...
Despite effective HIV medication, the immune system of people with HIV remains disrupted in the long term. Researchers at Amsterdam UMC investigated whether this dysregulation can be prevented by starting HIV medication immediately after infection – i.e. within a few days. They saw that six months after this early treatment, the immune system did indeed work as in people without HIV. But in the longer term, the immune system was disrupted again. This is shown by research by Amsterdam UMC, published in the journal EBioMedicine.
Early treatment protects immune systems only temporarily
For this study, the scientists examined ...
Record numbers of men and women globally are now estimated to have reduced kidney function, a new study shows. Figures rose from 378 million people with the disease in 1990 to 788 million in 2023 as the world population grew and aged, making it for the first time a top 10 cause of death worldwide.
Led by researchers at NYU Langone Health, the University of Glasgow, and the Institute for Health Metrics and Evaluation (IHME) at the University of Washington, the analysis explored the rise of the illness, in which the kidneys gradually lose their ability to filter waste and excess fluid from the blood. Mild cases may have no symptoms while the most severe stages ...
In 2023, chronic kidney disease (CKD) was the 9th-leading cause of death worldwide, responsible for nearly 1.5 million deaths.
Unlike most other leading causes of death, CKD mortality rates continue to rise, signaling a growing global health crisis.
In 2023, CKD ranked as the 12th-leading cause of disability worldwide and the 7th-leading driver of cardiovascular deaths. Kidney dysfunction alone accounted for almost 12% of all global cardiovascular deaths.
Diabetes, obesity, and high blood pressure remain the top drivers of CKD, alongside dietary risks and environmental factors.
SEATTLE, Wash. – Nov. 7, ...
About The Study: The results of this study suggest that community health workers played a vital role in improving patient engagement, emotional wellbeing, and self-efficacy, suggesting their integration into dialysis care teams may enhance holistic, patient-centered care.
Corresponding Author: To contact the corresponding author, Lilia Cervantes, MD, email Lilia.Cervantes@cuanschutz.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamanetworkopen.2025.48506)
Editor’s ...
About The Study: In this randomized clinical trial, a culturally tailored community health worker intervention modestly lowered interdialytic weight gain and improved dialysis adherence and patient activation among Hispanic and Latino patients with hemodialysis-dependent kidney failure.
Corresponding Author: To contact the corresponding author, Lilia Cervantes, MD, MSc, email lilia.cervantes@cuanschutz.edu.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
(doi:10.1001/jamainternmed.2025.5305)
Editor’s Note: Please see the article for additional information, including other authors, author ...
As China’s most important grain-producing region, Northeast China plays a vital role in safeguarding national food security. Yet this agricultural powerhouse faces a growing dilemma: how to maintain high crop yields while protecting the fragile ecosystems that sustain long-term productivity. A new study published in Agricultural Ecology and Environment identifies the key conflicts between agricultural expansion and ecological protection in the region and proposes integrated strategies to achieve a more sustainable balance.
Over the past four decades, Northeast China’s farmlands ...
SAN ANTONIO, Nov. 7, 2025 – Traumatic brain injury, or TBI, affects millions of Americans each year, often resulting in long-term health challenges. New national recommendations are now paving the way for more effective short- and long-term care for patients with TBI.
Monica Verduzco-Gutierrez, MD, a physiatrist with UT Health San Antonio, the academic health center of The University of Texas at San Antonio, and professor and chair of the Department of Physical Medicine and Rehabilitation at UT San Antonio’s Long School of Medicine, served on the National Academies of Sciences, ...
